These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 8912371

  • 1. Targeted therapy using alpha emitters.
    Vaidyanathan G, Zalutsky MR.
    Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
    [Abstract] [Full Text] [Related]

  • 2. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR, Bigner DD.
    Acta Oncol; 1996 Oct; 35(3):373-9. PubMed ID: 8679269
    [Abstract] [Full Text] [Related]

  • 3. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
    Zalutsky MR, Vaidyanathan G.
    Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
    Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, Stabin MG, Brechbiel MW.
    Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
    [Abstract] [Full Text] [Related]

  • 8. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
    Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, Ranieri P, Tsang M, Hou C, Li Y, Pawel B, Martinez D, Vaidyanathan G, Carlin S, Pryma DA, Maris JM.
    Clin Cancer Res; 2022 Sep 15; 28(18):4146-4157. PubMed ID: 35861867
    [Abstract] [Full Text] [Related]

  • 9. Astatine-211: production and availability.
    Zalutsky MR, Pruszynski M.
    Curr Radiopharm; 2011 Jul 15; 4(3):177-85. PubMed ID: 22201707
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec 15; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
    Strickland DK, Vaidyanathan G, Zalutsky MR.
    Cancer Res; 1994 Oct 15; 54(20):5414-9. PubMed ID: 7923174
    [Abstract] [Full Text] [Related]

  • 15. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J.
    Cancer Biother Radiopharm; 2014 Aug 15; 29(6):238-46. PubMed ID: 24971673
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
    Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD.
    Cancer Res; 1994 Sep 01; 54(17):4719-25. PubMed ID: 8062270
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
    Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, Horvath G.
    Anticancer Res; 2001 Sep 01; 21(1A):409-12. PubMed ID: 11299770
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 20. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
    Vaidyanathan G, Zhao XG, Larsen RH, Zalutsky MR.
    Br J Cancer; 1997 Jun 01; 76(2):226-33. PubMed ID: 9231923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.